vs

Side-by-side financial comparison of Direct Digital Holdings, Inc. (DRCT) and Silence Therapeutics plc (SLN). Click either name above to swap in a different company.

Silence Therapeutics plc is the larger business by last-quarter revenue ($15.7M vs $8.4M, roughly 1.9× Direct Digital Holdings, Inc.). Silence Therapeutics plc runs the higher net margin — -14.7% vs -138.7%, a 124.0% gap on every dollar of revenue.

Devolver Digital, Inc. is an American video game publisher based in Austin, Texas, specializing in the publishing of indie games. The company was founded in June 2009 by Nigel Lowrie, Harry Miller, Graeme Struthers, Rick Stults, and Mike Wilson, five executives who had been involved with Gathering of Developers and Gamecock Media Group, which published games on developer-friendly terms, but due to the high cost associated with releasing retail games saw themselves acquired and dissolved by la...

Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.

DRCT vs SLN — Head-to-Head

Bigger by revenue
SLN
SLN
1.9× larger
SLN
$15.7M
$8.4M
DRCT
Higher net margin
SLN
SLN
124.0% more per $
SLN
-14.7%
-138.7%
DRCT

Income Statement — Q4 FY2025 vs Q1 FY2024

Metric
DRCT
DRCT
SLN
SLN
Revenue
$8.4M
$15.7M
Net Profit
$-11.7M
$-2.3M
Gross Margin
26.8%
82.2%
Operating Margin
-53.4%
-35.6%
Net Margin
-138.7%
-14.7%
Revenue YoY
-7.4%
Net Profit YoY
-434.7%
EPS (diluted)
$-74.97
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DRCT
DRCT
SLN
SLN
Q4 25
$8.4M
Q3 25
$8.0M
Q2 25
$10.1M
Q1 25
$8.2M
Q4 24
$9.1M
Q3 24
$9.1M
Q2 24
$21.9M
Q1 24
$22.3M
$15.7M
Net Profit
DRCT
DRCT
SLN
SLN
Q4 25
$-11.7M
Q3 25
$-2.7M
Q2 25
$-2.2M
Q1 25
$-2.4M
Q4 24
$-2.2M
Q3 24
$-2.7M
Q2 24
$-590.0K
Q1 24
$-775.0K
$-2.3M
Gross Margin
DRCT
DRCT
SLN
SLN
Q4 25
26.8%
Q3 25
27.7%
Q2 25
35.1%
Q1 25
29.3%
Q4 24
32.5%
Q3 24
38.7%
Q2 24
27.1%
Q1 24
22.4%
82.2%
Operating Margin
DRCT
DRCT
SLN
SLN
Q4 25
-53.4%
Q3 25
-49.0%
Q2 25
-23.9%
Q1 25
-48.1%
Q4 24
-51.8%
Q3 24
-40.3%
Q2 24
-9.4%
Q1 24
-12.6%
-35.6%
Net Margin
DRCT
DRCT
SLN
SLN
Q4 25
-138.7%
Q3 25
-33.6%
Q2 25
-22.2%
Q1 25
-28.9%
Q4 24
-24.0%
Q3 24
-29.6%
Q2 24
-2.7%
Q1 24
-3.5%
-14.7%
EPS (diluted)
DRCT
DRCT
SLN
SLN
Q4 25
$-74.97
Q3 25
$-0.24
Q2 25
$-0.23
Q1 25
$-0.35
Q4 24
$-90.17
Q3 24
$-0.71
Q2 24
$-0.16
Q1 24
$-0.22
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DRCT
DRCT
SLN
SLN
Cash + ST InvestmentsLiquidity on hand
$728.0K
Total DebtLower is stronger
Stockholders' EquityBook value
$-7.0M
$156.8M
Total Assets
$20.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DRCT
DRCT
SLN
SLN
Q4 25
$728.0K
Q3 25
$871.0K
Q2 25
$1.6M
Q1 25
$1.8M
Q4 24
$1.4M
Q3 24
$4.1M
Q2 24
$1.1M
Q1 24
$3.3M
Total Debt
DRCT
DRCT
SLN
SLN
Q4 25
Q3 25
$10.8M
Q2 25
$33.5M
Q1 25
$32.9M
Q4 24
Q3 24
$150.0K
Q2 24
$34.8M
Q1 24
$32.4M
Stockholders' Equity
DRCT
DRCT
SLN
SLN
Q4 25
$-7.0M
Q3 25
$-6.7M
Q2 25
$-24.6M
Q1 25
$-23.3M
Q4 24
$-19.7M
Q3 24
$-16.7M
Q2 24
$-10.5M
Q1 24
$-7.5M
$156.8M
Total Assets
DRCT
DRCT
SLN
SLN
Q4 25
$20.2M
Q3 25
$22.5M
Q2 25
$23.3M
Q1 25
$23.8M
Q4 24
$26.0M
Q3 24
$31.3M
Q2 24
$48.5M
Q1 24
$52.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DRCT
DRCT
SLN
SLN
Operating Cash FlowLast quarter
$-1.9M
$-9.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DRCT
DRCT
SLN
SLN
Q4 25
$-1.9M
Q3 25
$-1.6M
Q2 25
$-2.7M
Q1 25
$-2.7M
Q4 24
$-1.6M
Q3 24
$3.0M
Q2 24
$-4.4M
Q1 24
$-5.7M
$-9.1M
Capex Intensity
DRCT
DRCT
SLN
SLN
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DRCT
DRCT

Buy Side Advertising$8.2M98%
Other$183.0K2%

SLN
SLN

Segment breakdown not available.

Related Comparisons